The ACO-optimized deep neural network shows exceptional accuracy for predicting blood-brain barrier permeability, enhancing CNS drug discovery.
The methodology provides a generalizable framework for optimizing complex machine learning models across various applications.
With advanced machine learning techniques, drug developers can better predict how well new medications can cross the blood-brain barrier.
Potential drug candidates can be screened more efficiently, saving time and resources in the drug development process.
Abstract
The ACO-Optimized DNN provides a highly accurate tool for virtual screening in CNS drug discovery, and the methodology serves as a generalizable template for complex model optimization.